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 LGMD2G is a rare disorders with only few cases described since now 
 We describe a new case of LGMD2G and perform an extensive review of the literature 
 We suggest a founder effect for TCAP c.90_91del mutation in the Mediterranean area 
 
ABSTRACT  
Limb girdle muscular dystrophy (LGMD) type 2G is a rare form of muscle disease, described only 
in a few patients worldwide, caused by mutations in TCAP gene, encoding the protein telethonin. It 
is characterized by proximal limb muscle weakness associated with distal involvement of lower 
limbs, starting in the first or second decade of life. 
We describe the case of a 37 year old woman of Greek origin, affected by disto-proximal lower 
limb weakness No cardiac or respiratory involvement was detected. Muscle biopsy showed 
myopathic changes with type I fibre hypotrophy, cytoplasmic vacuoles, lipid overload, multiple 
central nuclei and fibre splittings; ultrastructural examination showed metabolic abnormalities. Next 
generation sequencing analysis detected a homozygous frameshift mutation in the TCAP gene 
(c.90_91del), previously described in one Turkish family. Immunostaining and Western blot 
analysis showed complete absence of telethonin. Interestingly, Single Nucleotide Polymorphism 
analysis of the 10 MB genomic region containing the TCAP gene showed a shared homozygous 
haplotype of both the Greek and the Turkish patient, thus suggesting a possible founder effect of 
TCAP gene c.90_91del mutation in this part of the Mediterranean area. 
 
Keywords: Limb Girdle Muscular Dystrophy 2G, Telethonin, TCAP gene, founder effect. 
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1. Introduction 
Telethonin (or titin-cap) is a 19 kDa protein, consisting of 167 amino acids, encoded by the TCAP 
gene, which includes two exons and maps on chromosome 17q12 [1]. It is one of the most abundant 
transcripts in skeletal muscle and localizes to the Z-line of sarcomere in adult skeletal and cardiac 
muscles [2]. The protein is involved in normal sarcomere assembly and development, as well as in 
sarcomere-membrane interaction and signalling [1]. It interacts with the titin N-terminus, joining 
two antiparallel titin (Z1-Z2) domains together, and with other Z-disc proteins, such as LIM protein, 
Ankyrin Repeat Domain 2 protein, myostatin, potassium channel B subunit minK, protein kinase D, 
murine double minute 2. In the TCAP null mouse and in patients without telethonin expression [3-
4], the sarcomere architecture is generally normal. Pathogenesis seems to be related to disruption of 
sarcomere-T-tubular interaction, as shown in zebrafish models [5]. 
Mutations in the TCAP gene are responsible primarily for Limb Girdle Muscular Dystrophy 2G 
(OMIM 601954). Until now, only few families affected by LGMD2G have been described 
[Tab.1A-B]. LGMD2G is an extremely rare disease, originally described in the Brazilian population 
[4, 6-9] and subsequently reported in patients originating from China [10-11], Moldavia [12], 
Portugal [13], India [14-16], Spain [17] and Turkey [18]. 
LGMD2G phenotype is characterised by proximal limb muscles weakness associated with distal 
involvement of lower limbs with foot-drop. Atrophy generally involves muscles of thighs and the 
anterior compartment of the legs. Symptoms generally start in the first or second decade of life with 
lower limbs weakness. The disease is slowly progressive with 40% of patients loosing independent 
ambulation by the fourth decade. Calf hypertrophy and scapular winging are described in some 
patients; less frequently, contractures of Achilles tendons can occur. Creatine Kinase (CK) levels 
are usually increased (3-30x). Cardiac involvement is described only in a few cases [6] and 
pulmonary function is usually normal. Muscle biopsy shows dystrophic features, sometimes 
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associated with rimmed vacuoles. At immunostaining for telethonin, both partial reduction or 
absence of the protein were described. 
Mutations in TCAP gene can also be responsible for other clinical phenotypes. Recessive 
homozygous mutations have been reported in a few cases of Congenital Muscular Dystrophy [19-
21], and autosomal dominant missense mutations were described in patients with dilated and 
hypertrophic cardiomyopathy [22]. Patients with LGMD2G skeletal muscle phenotype mainly 
harbour frameshift or nonsense mutations with an autosomal recessive pattern of inheritance. 
 
2. Case report 
A 28 year-old-woman from Thessaly, Greece presented to medical attention for slowly progressive 
lower limb muscle weakness and atrophy. 
Her parents were third grade cousins. No family history of muscular disorders was detected, except 
for a sister of the grandfather with mild ambulatory difficulties. Birth and psychomotor 
development were normal; in adolescence, she even practiced martial arts. 
Symptoms started at 17 years of age with generalized muscle weakness and difficulties in walking 
and climbing stairs. Clinical evaluation, performed at age 28, revealed weakness and atrophy of the 
lower limbs, with major involvement of distal muscles (strength according to MRC scale: 
gastrocnemius 2/5, tibialis anterior 2+/5, first finger extensor 1/5) in comparison with proximal 
weakness ileopsoas 4/5 right, 4+/5 left, quadriceps 3+/5 right and 4+/5 left, biceps femoris 4+/5, 
adductors and abductors of hips 4+/5). There was no involvement of facial, bulbar and upper limb 
muscles. Tendon reflexes were absent in lower limbs and normal in upper limbs. The patient 
presented waddling gait along with hyperlordosis and needed a wheelchair to cover longer 
distances. She was not able to walk on heels and toes. 
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Muscle MRI of the lower limbs, performed at age 37, demonstrated diffuse and severe fibro-fatty 
substitution and atrophy of lower limbs muscle associated with a relative sparing of vastus lateralis, 
sartorius and soleus muscles (Fig.1). 
The disease showed a slowly progressive course. At 39 years of age, the patient presented further 
worsening of proximal lower limb weakness (MRC: tibialis anterior and gastrocnemius 0/5, 
quadriceps 3/5, iliopsoas 4/5), bilateral foot-drop and need of bilateral support during ambulation; 
however, the upper limbs were still spared. 
Creatine Kinase (CK) levels at onset were increased (2000 U/l) and remained elevated over time at 
follow-up (407-1200 U/l). Electromyography (EMG) showed myopathic changes. No cardiac or 
respiratory involvement was detected. Electrocardiogram showed incomplete right bundle branch 
block, echocardiogram was normal. The patient did not show any cognitive impairment. 
Two muscle biopsies were performed at age 22 and 30. Morphological examination was performed 
according to standard procedures [23]. The first muscle biopsy showed mild myopathic changes 
along with fibrosis. The second muscle biopsy in the left biceps brachii muscle revealed myopathic 
changes, type I fibre hypotrophy, multiple central nuclei, fibre splittings, rare cytoplasmic vacuoles, 
and lipid overload. Connective tissue was normal and no inflammatory infiltrates or necrosis were 
detected (Fig. 2A). Ultrastructural examination confirmed metabolic abnormalities characterised by 
a mild increase of intracellular lipids (Fig. 2E). Immunohistochemical analysis showed normal 
signal for caveolin-3, dysferlin, dystrophin, merosin, α and γ-sarcoglycan. Glycolytic enzymes were 
normal despite of metabolic alterations shown at electron microscopy. 
In order to exclude a possible cause of distal myopathy, the Glucosamine (UDP-N-Acetyl)-2-
Epimerase/N-Acetylmannosamine Kinase (GNE) gene was analysed with normal results. The 
sample of the patient was further studied with Next Generation Sequencing (NGS) techniques. 
DNA samples underwent MotorPlex protocol, analyzing the coding regions of 89 genes; 2x100 bp 
libraries were run on a HiSeq 1000 instrument (Illumina) and analyzed through a custom pipeline of 
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bioinformatics analyses [24-25]. We detected predicted pathogenic variants in MYBPC3 
(c.3589A>G; p.Thr1197Ala) and SYNE2 (c.976G>A; p.Asp326Asn) genes and a homozygous loss-of-
function change in TCAP (c.90_91del) gene. Considering clinical and histological features of the 
patient, the most likely pathogenic change among these was in TCAP. In fact the clinical 
phenotypes associated with MYBPC3 and SYNE2 mutations, respectively autosomal dominant 
cardiomyopathy and autosomal dominant Emery-Dreifuss muscular dystrophy phenotype, were not 
consistent with the clinical presentation of our patient. 
The mutation in TCAP gene is a homozygous 2 bp deletion in exon 1 which determines the 
frameshift of the transcript (p.Ser31HisfsX11). In order to confirm the inactivating effect of the 
mutation we performed immunostaining and Western-blot analysis of telethonin using Rabbit 
polyclonal anti TCAP antibodies (abCAM, ab121868 - Santa Cruz Biotechnology , Santa Cruz, 
CA). The analysis revealed complete absence of the protein with both methods (Fig. 2C; Fig 3). 
Unfortunately parental DNA was not available to confirm the segregation of the mutation, but the 
consanguinity and functional null effect of the mutation both support the homozygous status. 
Interestingly, the same variant has been recently identified [18] in a 35-year-old female patient of 
Turkish ethnicity with LGMD2G phenotype. In both cases, diagnosis was obtained by NGS 
approach. We revised the patient´s NGS data for informative markers located 5’and 3’ of the TCAP 
gene to investigate the presence of a possible founder effect. We identified a homozygous region 
extending at 3’ for 10Mb including the SGCA gene (Suppl. Fig. 1). 
 
3. Discussion  
LGMD2G is a very rare form of Limb Girdle Muscular Dystrophy with autosomal recessive 
inheritance. Until now, only 27 cases have been described, representing 15 independent patients, 
since in five families there was more than one affected person in the same generation (Tab.1A-B). 
The majority of these patients were of Brazilian descent, and the c.157C>T (p.Gln53X - exon 2) 
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mutation in homozygous state is the most frequent mutation. Although cases are rare world-wide, 
TCAP mutations are likely to occur in every continent. 
Here we describe a frameshift mutation in the TCAP gene causing a proximo-distal myopathy, 
which had been detected by next generation sequencing techniques. The clinical phenotype was 
consistent with LGMD2G, and absence of telethonin at WB analysis confirmed the diagnosis. 
Interestingly, the same mutation has been recently described in a 35-year-old Turkish girl with 
LGMD2G phenotype [18]. Markers reconstruction from NGS data in a 10 Mb genomic distance 
across the TCAP gene demonstrated an identical homozygous haplotype in these two patients, thus 
suggesting a possible founder effect for this recessive mutation. 
The description of our new case further confirms that this mutation is associated with the milder 
spectrum of the disease, showing onset of weakness in adolescence. So far, the mean age of 
weakness onset in the literature had been described with 8.5 ± 9.2 years of age (Tab 1), while the 
two patients with the c.90_91del mutation complained of weakness respectively at the age of 22 and 
17 years. This mutation, as well as all of others described so far in other LGMD2G subjects, is a 
truncating one, while dominant missense mutations are described in cases of cardiomyopathy [19]. 
The position of the new stop codon created by the mutation seems not be responsible for the 
phenotype, as well as the entity of protein reduction at Western-blot analysis. Although preliminary, 
these data argue against a direct correlation between mutation type, residual muscle protein level 
and clinical phenotype, as far as age at disease onset is concerned. Other modulating factors might 
be involved in determining part of the clinical variability. Interestingly, tendon contractures and 
myalgia were not seen in our patient, while these symptoms already had appeared at a very young 
age (2 years of age) in the patient described by Ikenberg et al [18]. Upper extremities were spared 
in both cases at last evaluation, respectively at 39 and 34 years, which is atypically mild for 
LGMD2G, since none of the patients previously described had a similar distribution at last 
evaluation. 
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On the contrary, distal involvement is frequently described in LGMD2G patients, sometimes also at 
early stages [6-14-19], especially in lower limbs, presenting with foot-drop and involvement of 
tibialis anterior muscles. As well as in our patient, this feature was predominant also in other 
subjects with LGMD2G [6-17]. Respiratory involvement or cardiomyopathy was not reported in 
both cases, consistently with the majority of previous reports; extrasystolia had been described only 
in the Turkish patient. CK levels were similar to those detected in other patients (x2-50). Sparing of 
the sartorius muscle was seen in both muscle MRIs as described previously [12-14; 17]. 
The muscle biopsy of our patient showed a pattern consistent with other cases of LGMD2G 
reported in literature, with type I fibre atrophy, central nuclei, fibre splittings and myopathic 
changes without connective tissue increase and normal sarcomeric structure [4, 9, 13]. We did 
neither detect lobulated fibres nor classical rimmed vacuoles, as seen in other reports [4, 9, 13]. 
However, we detected rare cytoplasmic vacuoles and lipid overload, confirmed by ultrastructural 
examination showing metabolic abnormalities such as mild increase of intracellular lipids (Fig. 2E). 
Glycogen deposits and metabolic alterations were an atypical finding, since until now, focal 
intrasarcoplasmic glycogen deposits were only described once in LGMD2G [9]. This additional 
finding in our patient enlarges the morphological spectrum of the disease. 
 
4. Conclusion  
This case both contributes to consolidate a typical phenotype of LGMD2G and further expands the 
clinical spectrum of LGMD2G, since it confirms that also milder forms of the disease may exists. 
Moreover it suggests a founder effect for the TCAP c.90_91del mutation. Although 
telethoninopathy is not a frequent cause of muscular dystrophy - in our previously described LGMD 
cohort [26] it accounts only to 1% of LGMD patients - it is useful to consider this form of LGMD 
in the differential diagnosis, especially in patients presenting with distal involvement of the lower 
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limbs. Interestingly, the muscle biopsy of our patient presented some atypical features, expanding 
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FIGURE LEGENDS 
Fig.1 Muscle imaging. Muscle MRI axial T1 images at thigh (A) and calf (B) level demonstrated 
diffuse and severe fibro-fatty substitution and atrophy associated with relative sparing of vastus 
lateralis, sartorius and soleus. 
 
Fig.2 Muscle biopsy 
Biceps muscle biopsy revealed myopathic signs with type I fibre hypotrophy, size variability, 
multiple nuclear centralization, fibre splittings rare cytoplasmic vacuoles and lipid overload (A 
Gomori Trichrome 40x and inhomogeneous enzymatic activity distribution (NADH-TR: B 40x and 
F. 20x ). IHC analysis with Rabbit polyclonal anti TCAP antibodies showed absence of signal in the 
patient (C) compared to control (D). Ultrastructural analysis showed small lipid droplets in rare 
muscle fibers (E bar 700 nm; 7000 x) 
 
Fig. 3 Western-blot analysis. Telethonin Western-blot analysis showed protein absence in the 
patient sample (pt) compared to control (Ctr)  
 
Suppl. Fig.1 Haplotype analysis  
The analysis of the informative markers located 5’and 3’ of TCAP in our patient (A) and in the 
patient described by Ikenberg et al. (B), showed a homozygous region extending at 3’ for 10Mb 
including the SGCA gene suggesting a possible founder effect. The variants with the same state of 
zygosity in both patients are highlighted in green. 
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Fig. 1 Muscle MRI.tif 
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Fig. 3 Western blot.jpg 
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Fig.2 biopsy R January.jpg 
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Suppl Fig 1 Jan.jpg 
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